Authorized purpose: PixelShine is intended for networking, communication, processing, and enhancement of CT images in DICOM format to assist professional radiologists and specialists in reaching their own diagnosis. Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not intended for diagnostic interpretation of mammography images.
Clinical role
Medical-image display, manipulation, segmentation, quantification, comparison, reporting, or workflow support under professional review.
Images and patients
CT/CTA · CT images represented in DICOM format
Key limitation
Keep in mind: Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: PixelShine is intended for networking, communication, processing, and enhancement of CT images in DICOM format to assist professional radiologists and specialists in reaching their own diagnosis. Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not intended for diagnostic interpretation of mammography images.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: CT images represented in DICOM format Input: Supported DICOM images, image metadata, patient data, and user inputs from the labeled imaging devices.
Who uses it?Intended users: Radiologists, physicians, technologists, and other trained medical professionals within the labeled workflow.
What does the software produce?Output: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
What is its most important limitation?Key limitation: Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
Clinical takeaway. Clinical role: PixelShine is intended for networking, communication, processing, and enhancement of CT images in DICOM format to assist professional radiologists and specialists in reaching their own diagnosis. Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not intended for diagnostic interpretation of mammography images.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports only non-clinical testing: PixelShine performance was validated through phantoms and comparison of collected image data to ascertain image quality, and non-clinical performance testing under an approved testing protocol was performed with satisfactory results; the device was designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
PixelShine is intended for networking, communication, processing, and enhancement of CT images in DICOM format to assist professional radiologists and specialists in reaching their own diagnosis. Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not intended for diagnostic interpretation of mammography images.
Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
The exact FDA document reports only non-clinical testing: PixelShine performance was validated through phantoms and comparison of collected image data to ascertain image quality, and non-clinical performance testing under an approved testing protocol was performed with satisfactory results; the device was designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The PixelShine performance has been validated through the use of phantoms and the comparison of collected image data to ascertain image quality." … "The following non-clinical performance testing was performed with satisfactory results. All of the testing was performed with the use of an approved testing protocol.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports only non-clinical testing: PixelShine performance was validated through phantoms and comparison of collected image data to ascertain image quality, and non-clinical performance testing under an approved testing protocol was performed with satisfactory results; the device was designed, verified and validated in compliance with 21 CFR, Part 820.30 requirements. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The PixelShine performance has been validated through the use of phantoms and the comparison of collected image data to ascertain image quality." … "The following non-clinical performance testing was performed with satisfactory results. All of the testing was performed with the use of an approved testing protocol.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K161625 FDA decision evidence package for PixelShine
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationCT images represented in DICOM format
Scopeexact submission
Tested versionPixelShine configuration described in K161625
IndependenceSponsor or vendor study
K161625
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K161625 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM images, image metadata, patient data, and user inputs from the labeled imaging devices.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes a DICOM server on a Linux-based network server that receives CT images from DICOM devices and sends processed images to destination DICOM devices or PACS; verify patient matching, routing, archive, and downtime behavior locally.
Scope: Exact FDA submission. This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes installation by trained personnel on an AlgoMedica-specified off-the-shelf PC with Linux and two network ports; current hosting, service, security, and site configuration remain unknown.
Scope: Exact FDA submission. This is a partial release-level topology fact from the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Displayed images, reformats, segmentations, measurements, annotations, reports, and workflow records for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes installation by trained personnel on an AlgoMedica-specified off-the-shelf PC with Linux and two network ports; current hosting, service, security, and site configuration remain unknown.
Exact FDA submission
Checked 2026-09-04
This is a partial release-level topology fact from the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
The exact FDA package describes a DICOM server on a Linux-based network server that receives CT images from DICOM devices and sends processed images to destination DICOM devices or PACS; verify patient matching, routing, archive, and downtime behavior locally.
Exact FDA submission
Checked 2026-09-04
This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Only radiologists, physicians, technologists, and other trained medical professionals within the labeled workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K161625 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact FDA package describes installation by trained personnel on an AlgoMedica-specified off-the-shelf PC with Linux and two network ports; current hosting, service, security, and site configuration remain unknown.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA package describes a DICOM server on a Linux-based network server that receives CT images from DICOM devices and sends processed images to destination DICOM devices or PACS; verify patient matching, routing, archive, and downtime behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Monitor K161625 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Processing is not effective for lesions, masses, or abnormalities smaller than 3 mm, and the device is not for diagnostic interpretation of mammography images.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
12Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 12 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.
Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.
Authorized purpose: Passive workflow prioritization for studies with imaging patterns consistent with possible total arterial occlusion in the specified vessels; not primary diagnosis, screening, disease detection, or patient-management decision support
Modality
CT/CTA
Anatomy
Aorta and lower-extremity arteries: common iliac, external iliac, common femoral, superficial femoral, and popliteal arteries
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.